Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |16 October 2012

Therapy for Patients With Familial Mediterranean Fever When Colchicine Is Not Enough or Is Not Tolerated Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
  • The full report is titled “Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever. A Randomized Trial.” It is in the 16 October 2012 issue of Annals of Internal Medicine (volume 157, pages 533-541). The authors are P.J. Hashkes, S.J. Spalding, E.H. Giannini, B. Huang, A. Johnson, G. Park, K.S. Barron, M.H. Weisman, N. Pashinian, A.O. Reiff, J. Samuels, D.A. Wright, D.L. Kastner, and D.J. Lovell.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Familial Mediterranean fever (FMF) is a rare disease that causes repeated bouts of fever and accumulations of fluid in the body, causing pain in the joints, abdomen, chest, and other sites. There is no known cure for the disease, but many patients have a decrease in the number of attacks with a drug called colchicine. Some patients, however, do not experience enough relief with colchicine or have problematic side effects, making its use difficult or impossible. At present, there is no known therapy for such patients. Familial Mediterranean fever is caused by abnormalities in a gene that controls the action of a chemical involved in inflammation called interleukin-1.

Why did the researchers do this particular study?

To see whether rilonacept, a drug that can stop the function of interleukin-1, may help patients with FMF who cannot tolerate colchicine or have attacks despite its use.

Who was studied?

14 patients with FMF who could not tolerate colchicine or had continued attacks while taking it.

How was the study done?

After 1 to 3 months of observation on current therapies to see how many attacks were normally experienced at “baseline,” each patient received rilonacept injections under the skin each week for 3 months as well as a 3-month period of placebo injections; each 3-month treatment was repeated. The order of treatments was randomized, and neither the patients nor the doctors knew which one was being received. During each 3-month period, the number of FMF attacks was monitored. Patients (or their parents, if the patients were children) also assessed the effect of FMF on their quality of life during the treatment periods.

What did the researchers find?

During the treatment periods with rilonacept, patients had fewer attacks of FMF than with placebo, and more patients had a decrease to less than one half of their previous baseline number. Patients also reported better physical aspects of quality of life with rilonacept. Patients had pain with the rilonacept injections more often than with placebo, although all of these reactions were considered mild by the patients.

What were the limitations of the study?

Because FMF is a rare disease, there were few patients in the study and there may be differences between these patients and others with the disease. In addition, the study was not large enough to assess whether patients with certain gene abnormalities causing FMF are more likely to respond to rilonacept. The study could not assess how long the effect of rilonacept may last or whether there are long-term safety problems. It is also not known whether rilonacept can help prevent other long-term health problems in FMF that colchicine can prevent.

What are the implications of the study?

Rilonacept may be a treatment option for patients with FMF who cannot tolerate colchicine or have attacks despite its use.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Therapy for Patients With Familial Mediterranean Fever When Colchicine Is Not Enough or Is Not Tolerated. Ann Intern Med. 2012;157:I–44. doi: https://doi.org/10.7326/0003-4819-157-8-201210160-00001

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2012;157(8):I-44.

DOI: 10.7326/0003-4819-157-8-201210160-00001

0 Citations

See Also

Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Randomized Trial
View MoreView Less

Related Articles

Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Randomized Trial
Annals of Internal Medicine; 157 (8): 533-541
Efficacy of Intermittent Colchicine Therapy in Familial Mediterranean Fever
Annals of Internal Medicine; 86 (2): 162-165
Prophylactic Colchicine Therapy in Familial Mediterranean Fever: A Controlled, Double-Blind Study
Annals of Internal Medicine; 81 (6): 792-794
Statistical Code to Support the Scientific Story
Annals of Internal Medicine; 168 (11): 828-829
View MoreView Less

Journal Club

Guideline: In acute gout, steroids, NSAIDs, or low-dose colchicine recommended; lifestyle changes not supported
Annals of Internal Medicine; 166 (4): JC14
Colchicine reduced further recurrence after a first recurrence of pericarditis
Annals of Internal Medicine; 156 (4): JC2-4
Adding colchicine to standard therapy after cardiac surgery reduced risk for the postpericardiotomy syndrome
Annals of Internal Medicine; 154 (4): JC2-10
View MoreView Less

Related Topics

Rheumatology

Rheumatology.

PubMed Articles

The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors.
Molecules 2019;24(23):.
Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care.
Ann Rheum Dis 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×